

THE USE OF GROWTH HORMONE SECRETAGOGUES TO  
TREAT SYSTEMIC LUPUS ERYTHEMATOSUS AND  
INFLAMMATORY BOWEL DISEASE

5 FIELD OF THE INVENTION

This application claims priority from the provisional application U.S. serial number 60/212,521, filed on June 19, 2000, the benefit of which is hereby claimed under 37 C.F.R. § 1.78(a)(3).

10 The present invention provides methods of using growth hormone secretagogues, prodrugs thereof and pharmaceutically acceptable salts of said secretagogues and said prodrugs to treat systemic lupus erythematosus, Crohn's disease, inflammatory bowel disease (IBD) and ulcerative colitis. More specifically, the present invention provides such methods wherein the growth hormone secretagogues are certain compounds of Formula I below. This invention also  
15 provides combinations comprising a growth hormone secretagogue and a second therapeutic agent selected from methotrexate, dapsone, a glucocorticoid or an antimalarial. The invention also provides pharmaceutical compositions and kits comprising such combinations and methods of using such combinations, pharmaceutical compositions and kits in the treatment of systemic lupus  
20 erythematosus, Crohn's disease, IBD and ulcerative colitis.

BACKGROUND OF THE INVENTION

Systemic Lupus Erythematosus (SLE), also known as disseminated lupus erythematosus or, simply, lupus, is a chronic, usually life-long, potentially fatal  
25 autoimmune disease characterized by unpredictable exacerbations and remissions with protean clinical manifestations. SLE is also characterized by immune dysregulation resulting in the production of antinuclear antibodies (ANA), generation of circulating immune complexes, and activation of the complement system. In SLE there is a predilection for clinical involvement of the joints, skin, kidney, brain, serosa,  
30 lung, heart and gastrointestinal tract. The pathologic hallmark of the disease is recurrent, widespread, and diverse vascular lesions. Women and minorities are disproportionately affected and SLE is most common in women of child-bearing age although it has been reported in both extremes of life (e.g. diagnosed in infants and in the tenth decade of life). The number of persons suffering from SLE in the United

States is reported variously from about 500,000 to about 2,000,000. (H. Michael Belmont, Clinical Overview of Lupus, <http://cerebel.com/lupus/overview.html>.)

The prognosis for patients with SLE has greatly improved over the last few decades with at least 80-90% of all patients surviving ten years. Thereafter, life expectancy approximates that of age matched controls. This improvement reflects the general advancements in health care (e.g. dialysis, antibiotics, antihypertensives, newer immunosuppressives with more favorable efficacy to toxicity ration) but also the specialized care available for patients with SLE. (Belmont, *ibid.*)

SLE is a complex disorder affecting a predominately young population and shares similarities with HIV infection as regards the propensity for multiple organ involvement, potentially life-threatening episodes, and need for sophisticated monitoring. (Belmont, *ibid.*)

SLE is not a rare disorder. Although reported at both extremes of life (e.g., diagnosed in infants and in the tenth decade of life), chiefly it affects women of child bearing age. Among children, SLE occurs three times more commonly in females than in males. In the 60% of SLE patients who experience onset of their disease between puberty and the fourth decade of life the female to male ratio is 9:1. Thereafter, the female preponderance again falls to that observed in prepubescents. (Belmont, *ibid.*)

The etiology of SLE remains unknown. A genetic predisposition, sex hormones, and environmental trigger(s) likely result in the disordered immune response that typifies the disease. (Belmont, *ibid.*)

A role for genetics is suggested by the increased percentage of two histocompatibility antigens in patients with SLE, HLA-DR2 and HLA-DR3. In addition, there is an increased frequency of the extended haplotype HLA-A1, B8, DR3. The role for heredity is further supported by the concordance for this illness among monozygotic twins. The polygenic nature, however, of this genetic predisposition as well as the contribution of environmental factors is suggested by the only moderate concordance rate which is reported to be between 25 and 60%. (Belmont, *ibid.*)

The origin of autoantibody production in SLE is unclear but a role has been suggested for an antigen driven process, spontaneous B-cell hyper-responsiveness, or impaired immune regulation. Regardless of the etiology of autoantibody production, SLE is associated with the impaired clearance of circulating immune complexes secondary to decreased CR1 expression, defective Fc receptor function,

or deficiencies of early complement components such as C4A. (Belmont, *ibid.*) It has been suggested that the apoptosis process is atypical in the lupus patient leading to the increased production of autoantibodies including antiphospholipid antibodies. (L. Casciola-Rosen et al., Proc. Natl. Acad. Sci. USA, **93**, 1996, 1624-1629.

5 The health status of a patient with SLE is related not only to disease activity, but to the damage that results from recurrent episodes of disease flare (e.g., deforming arthropathy, shrinking lung, end stage renal disease, organic mental syndrome, etc.), as well as the adverse effects of treatment (e.g., avascular necrosis of bone, infections, precocious atherosclerosis, etc.). (H. Michael Belmont, Clinical Overview  
10 of Lupus, <http://cerebel.com/lupus/overview.html>.)

Current therapy for SLE consists of treatment with antimalarials, methotrexate, dapsone, corticosteroids and/or glucocorticoids. These treatments suffer from the drawback that the disease is not adequately controlled and that each of the current treatments have known serious side effects. For example, long term  
15 corticosteroid use can lead to osteoporosis, high blood pressure, arterial damage, increased risk of infection and cataracts. (<http://www.nih.gov/niams/healthinfo/>).

Inflammatory Bowel Disease is a term used to collectively describe Crohn's disease and ulcerative colitis, both of which cause similar symptoms, particularly inflammation of the intestines.

20 Crohn's disease is a debilitating multisystem disorder which is characterized by inflammation of the bowel. The disease usually begins during adolescence or early adulthood and often leads to catabolism. Generally, patients suffering from Crohn's disease are treated with immunosuppressive and antiinflammatory drugs that often have severe side effects which may enhance the catabolic process. High protein  
25 diets have been partially successful in counteracting the effects of the disease. It has been reported that growth hormone and insulin-like growth factor I<sup>4</sup> counteract the catabolic process of the disease and reduce morbidity. See Slonim et al., New England Journal of Medicine, 2000, **342**, 1633-1637. Crohn's disease and ulcerative colitis are currently treated by administering prednisone, sulfasalazine (which is sold  
30 in a commercial formulation as Azulfidine®), mesalamine (which is variously sold in commercial formulations as, *inter alia*, Asacol®, Pentasa® and Rowasa®) and olsalazine (which is sold in a commercial formulation as Dipentum®).

Ulcerative colitis is a condition characterized by inflammation of the lining of the colon and/or rectum. The inflammation may be of long or short duration and

varies in intensity. Remission, the period between flare-ups, may last for a few days to many years. Patients generally experience bloody diarrhea, rectal bleeding, abdominal pain or cramping and/or and urgent need to go to the bathroom. The condition is a life-long problem which has no cure short of removal of the colon. The periods of remission may be extended by treatment with prednisone, sulfasalazine (which is sold in a commercial formulation as Azulfidine®), mesalamine (which is variously sold in commercial formulations as, *inter alia*, Asacol®, Pentasa® and Rowasa®) and olsalazine (which is sold in a commercial formulation as Dipentum®). (<http://www.living-better.com/2010.html>). Overexpression of bovine growth hormone in transgenic mice accelerates recovery and mucosal healing after experimentally induced colitis. See Williams et al., Gastroenterology 2000, **118**, A556.

Growth hormone (GH), which is secreted from the pituitary, stimulates growth of all tissues of the body that are capable of growing. In addition, growth hormone is known to have the following basic effects on the metabolic processes of the body: (1) increased rate of protein synthesis in all cells of the body; (2) decreased rate of carbohydrate utilization in cells of the body; and (3) increased mobilization of free fatty acids and use of fatty acids for energy.

GH receptors are found throughout the stomach, small intestine and colon. GH has a proliferative effect on intestinal crypt cells. Pair-fed transgenic mice overexpressing growth hormone show increases in small bowel weight and length and a 50% - 100% increase in mucosal mass with increased villus height and crypt depth, particularly in the proximal bowel. GH increases absorption or transport of water, sodium chloride, amino acids and calcium in the gut and increases enteroendocrine secretion in animals. See Shulman, Endocrine 2000, **12**(2): 147-152.

In preliminary clinical trials of short bowel syndrome, GH in combination with glutamine and dietary supplementation improved fractional protein absorption and decreased stool output. See Byrne et al., Ann Surg 1995, **222**: 243-0255. High dose GH therapy improves survival in patients with severe hemorrhage from gastric stress ulcers. See Winawer et al., Arch Int Med 1975 **135**:569-572.

Various ways are known to release growth hormone (see Recent Progress in Hormone Research, vol. 52, pp. 215-245 (1997); and Front Horm Res. Basel, Karger, vol. 24, pp. 152-175 (1999)). For example, chemicals such as arginine, L-3,4-dihydroxyphenylalanine (L-DOPA), glucagon, vasopressin, and insulin induced hypoglycemia, as well as activities such as sleep and exercise, indirectly cause

growth hormone to be released from the pituitary by acting in some fashion on the hypothalamus perhaps either to decrease somatostatin secretion or to increase the secretion of the known growth hormone secretagogue, growth hormone releasing factor (GRF), or the endogenous growth hormone-releasing hormone, ghrelin (see Nature, vol. 402, pp. 656-660 (9 December 1999), or all of these.

In cases where increased levels of growth hormone were desired, the problem was generally solved by providing exogenous growth hormone or by administering GRF, IGF-I or a peptidyl compound which stimulated growth hormone production and/or release. In any case, the peptidyl nature of the compound necessitated that it be administered by injection. Initially, the source of growth hormone was the extraction of the pituitary glands of cadavers. This resulted in a very expensive product and carried with it the risk that a disease associated with the source of the pituitary gland could be transmitted to the recipient of the growth hormone. Recombinant growth hormone has become available which, while no longer carrying any risk of disease transmission, is still a very expensive product which must be given by injection or by a nasal spray. In addition, administration of exogenous growth hormone may result in side-effects, including edema, and does not correlate with the pulsatile release seen in the endogenous release of growth hormone.

Certain compounds have been developed which stimulate the release of endogenous growth hormone. Peptides which are known to stimulate the release of endogenous growth hormone include growth hormone releasing hormone, the growth hormone releasing peptides, GHRP-6 and GHRP-1 (described in U.S. Patent No. 4,411,890; International Patent Application, Publication No. WO 89/07110; and International Patent Application, Publication No. WO 89/07111), and GHRP-2 (described in International Patent Application, Publication No. WO 93/04081), as well as hexarelin (J. Endocrinol. Invest., 15 (Suppl. 4): 45 (1992)). Other compounds possessing growth hormone secretagogue activity are disclosed in the following International Patent Applications (listed by Publication Nos.), issued U.S. Patents or published European Patent Applications: WO 98/46569, WO 98/51687, WO 96/38471, WO 96/35713, WO 98/58947, WO 98/58949, WO 98/58950, WO 99/08697, WO 99/09991, WO 95/13069, U.S. 5,492,916, U.S. 5,494,919, WO 95/14666, WO 94/19367, WO 94/13696, WO 94/11012, U.S. 5,726,319, WO 95/11029, WO 95/17422, WO 95/17423, WO 95/34311, WO 96/02530, WO

96/22996, WO 96/22997, WO 96/24580, WO 96/24587, U.S. 5,559,128, WO 96/32943, WO 96/33189, WO 96/15148, WO 97/00894, WO 97/07117, WO 97/06803, WO 97/11697, WO 97/15573, WO 97/22367, WO 97/23508, WO 97/22620, WO 97/22004, WO 97/21730, WO 97/24369, U.S. 5,663,171, WO 97/34604, WO 97/36873, WO 97/40071, WO 97/40023, WO 97/41878, WO97/41879, WO 97/46252, WO 97/44042, WO 97/38709, WO 98/03473, WO 97/43278, U.S. 5,721,251, U.S. 5,721,250, WO 98/10653, U.S. 5,919,777, U.S. 5,830,433 and EP 0995748.

In addition, the following growth hormone secretagogues are known in the art:

MK-0677 (Merck); NN703 (Novo Nordisk); L-162752 and L-163022 (Merck); hexarelin (Pharmacia & Upjohn); GPA-748 (KP102, GHRP-2) (American Home Products); ipamorelin (Novo Nordisk); and LY444711 (Eli Lilly). The following agents that stimulate GH release via GHRH/GRF receptor (including GHRH/GRF derivatives, analogs and mimetics) are known in the art: Geref (Ares/Serono); GHRH (1-44) (BioNebraska); Somatorelin (GRF 1-44) (Fujisawa/ICN); and ThGRF (Theratechnologies).

Endocrine Reviews 18(5): 621-645 (1997) provides an overview of peptidomimetic regulation of growth hormone secretion by growth hormone secretagogues. Horm. Res. 1999; 51(suppl 3):16-20 (1999), examines the clinical and experimental effects of growth hormone secretagogues on various organ systems.

As is well known to those skilled in the art, the known and potential uses of growth hormone are varied and multitudinous. See "Human Growth Hormone," Strobel and Thomas, Pharmacological Reviews, 46, pg. 1-34 (1994). Also, these varied uses of growth hormone are summarized in International Patent Application, Publication Number WO 97/24369.

International Patent Applications, Publication Numbers WO 97/24369 and WO 98/58947 disclose that certain growth hormone secretagogues are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.

Published European patent application 0995748 discloses that certain dipeptide growth hormone secretagogues are useful for the treatment or prevention of musculoskeletal frailty, including osteoporosis.

The administration of a growth hormone secretagogue is also known to enhance the quality of sleep, which is disclosed in International Patent Application Publication Number WO 97/24369. Commonly assigned U.S. nonprovisional patent application 09/290985, filed 13 April 1999, discloses pharmaceutical compositions comprising certain  $\beta_3$  adrenergic agonists and growth hormone secretagogues or growth hormone, and their use for treating diabetes, obesity, hyperglycemia, frailty associated with obesity or frailty associated with aging, and for enhancing the quality of sleep in a mammal. International Patent Application Publication Number WO 98/58949 discloses the treatment of insulin resistance with certain growth hormone secretagogues.

International Patent Application Publication Number WO 00/12407 discloses that a growth hormone secretagogue is useful for enhancing the return of patients to independent living status following acute deconditioning such as that which may result from immobilization, surgery, or major injury such as hip fracture.

Journal of Orthopaedic Research 15:519:527 (1997) discloses that a growth hormone secretagogue, MK-0677, elevated levels of serum insulin-like growth factor-1, which in turn increased the size and strength of the quadriceps muscle in canines during remobilization.

J. Bone Miner. Res. 1998, 12: 1158-1166 discloses that treatment with the oral growth hormone secretagogue, MK-0677, increases markers of bone formation and bone resorption in obese young males.

Bone 23(5) (Supplement), Abstract F235 from ASBMR/IBMS Joint Meeting (November 1998), discloses that the growth hormone secretagogues, GHRP-6 and Ipamorelin (IPA) have the capacity to increase bone mass in adult female rats.

U.S. Patent Number 6,043,026 (28 March 2000) discloses that the combination of an estrogen receptor modulator and a growth hormone secretagogue is useful in the treatment or prevention of diseases involving bone resorption, especially osteoporosis.

R. Bross et al., J. Clin. Endocrinol. Metab., 84:3420-3430 (1999) discusses the potential use of human growth hormone supplementation for the treatment of aging-associated sarcopenia.

## SUMMARY OF THE INVENTION

5           This invention is directed to methods of treating systemic lupus erythematosus in a patient which comprises administering to the patient a systemic lupus erythematosus treating effective amount of a growth hormone secretagogue (GHS), a prodrug thereof or a pharmaceutically acceptable salt of said GHS or said prodrug.

10           This invention is also directed to methods of treating inflammatory bowel disease such as Crohn's disease and ulcerative colitis in a patient which comprises administering to the patient an inflammatory bowel disease treating effective amount of a growth hormone secretagogue (GHS), a prodrug thereof or a pharmaceutically acceptable salt of said GHS or said prodrug.

15           The GHS may be peptidyl or non-peptidyl in nature, however, the use of an orally active GHS is preferred. In addition, it is preferred that the GHS induce or amplify a pulsatile release of endogenous growth hormone.

            This invention is also directed to combinations comprising a GHS, a prodrug thereof or a pharmaceutically acceptable salt of said GHS or said prodrug and a  
20           second therapeutic agent wherein said second therapeutic agent is known to be beneficial in the treatment of systemic lupus erythematosus. Preferred such agents include, but are not limited to, methotrexate, dapsone, a glucocorticoid or an antimalarial, a prodrug of said methotrexate, dapsone, glucocorticoid or antimalarial or a pharmaceutically acceptable salt thereof or of said prodrug. This invention is also  
25           directed to pharmaceutical compositions comprising such combinations and a pharmaceutically acceptable carrier, vehicle or diluent.

            This invention is also directed to a kit comprising:

- a)           a first unit dosage form comprising a GHS, a prodrug thereof or a pharmaceutically acceptable salt of said GHS or said prodrug and a  
30           pharmaceutically acceptable carrier, vehicle or diluent;
- b)           a second unit dosage form comprising methotrexate, dapsone, a glucocorticoid or an antimalarial, a prodrug thereof or a pharmaceutically acceptable salt of methotrexate, dapsone, glucocorticoid or antimalarial or said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent; and



c) a container.

This invention is also directed to methods of treating systemic lupus erythematosus in a patient which comprises administering to the patient

5 a) a pharmaceutical composition comprising a GHS, a prodrug thereof or a pharmaceutically acceptable salt of said GHS or said prodrug; and methotrexate, dapsone, a glucocorticoid or an antimalarial, a prodrug thereof or a pharmaceutically acceptable salt of methotrexate, dapsone, glucocorticoid or antimalarial or said prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent ;

10 b) a GHS, a prodrug thereof or a pharmaceutically acceptable salt of said GHS or said prodrug or a pharmaceutical composition thereof; and methotrexate, dapsone, a glucocorticoid or an antimalarial, a prodrug thereof or a pharmaceutically acceptable salt of said methotrexate, dapsone, glucocorticoid or antimalarial or said prodrug or a pharmaceutical composition thereof; or

15 c) a kit as described herein. This invention thus includes methods whereby a fixed combination is administered and methods whereby the individual components of the combination are administered separately.

This invention is also directed to combinations comprising a GHS, a prodrug thereof or a pharmaceutically acceptable salt of said GHS or said prodrug and a  
20 second therapeutic agent wherein said second therapeutic agent is known to be beneficial in the treatment of inflammatory bowel disease such as Crohn's disease or ulcerative colitis. Preferred such agents include, but are not limited to, prednisone, sulfasalazine, mesalamine and olsalazine, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug and a pharmaceutically acceptable  
25 carrier, vehicle or diluent.

This invention is also directed to pharmaceutical compositions comprising such combinations and a pharmaceutically acceptable carrier, vehicle or diluent.

This invention is also directed to a kit comprising:

30 a) a first unit dosage form comprising a GHS, a prodrug thereof or a pharmaceutically acceptable salt of said GHS or said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent;

b) a second unit dosage form comprising an agent selected from prednisone, sulfasalazine, mesalamine and olsalazine, a prodrug thereof or a

pharmaceutically acceptable salt of said agent or said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent; and

c) a container.


This invention is also directed to methods of treating inflammatory bowel disease such as Crohn's disease or ulcerative colitis in a patient which comprises administering to the patient

a) a pharmaceutical composition comprising a GHS, a prodrug thereof or a pharmaceutically acceptable salt of said GHS or said prodrug; and an agent selected from prednisone, sulfasalazine, mesalamine and olsalazine, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent;

b) a GHS, a prodrug thereof or a pharmaceutically acceptable salt of said GHS or said prodrug or a pharmaceutical composition thereof; and an agent selected from prednisone, sulfasalazine, mesalamine and olsalazine, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug or a pharmaceutical composition thereof; or




c) a kit as described herein. This invention thus includes methods whereby a fixed combination is administered and methods whereby the individual components of the combination are administered separately.

In the combinations, methods, pharmaceutical compositions and kits of this invention, it is preferred that the GHS is a compound of the Formula I:




or a stereoisomeric mixture thereof, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomer thereof, or a prodrug of such compound, mixture or isomer thereof, or a pharmaceutically acceptable salt of the compound, mixture, isomer or prodrug, wherein:

HET is a heterocyclic moiety selected from the group consisting of



and



d is 0, 1 or 2;

e is 1 or 2;

f is 0 or 1;

5 n and w are 0, 1 or 2, provided that n and w cannot both be 0 at the same time;

Y<sup>2</sup> is oxygen or sulfur;

A is a divalent radical, where the left hand side of the radical as shown below is connected to C<sup>n</sup> and the right hand side of the radical as shown below is connected to C<sup>r</sup>, selected from the group consisting of

- 10 -NR<sup>2</sup>-C(O)-NR<sup>2</sup>-, -NR<sup>2</sup>-S(O)<sub>2</sub>-NR<sup>2</sup>-, -O-C(O)-NR<sup>2</sup>-, -NR<sup>2</sup>-C(O)-O-, -C(O)-NR<sup>2</sup>-C(O)-, -C(O)-NR<sup>2</sup>-C(R<sup>9</sup>R<sup>10</sup>)-, -C(R<sup>9</sup>R<sup>10</sup>)-NR<sup>2</sup>-C(O)-, -C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-, -S(O)<sub>2</sub>-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-, -C(R<sup>9</sup>R<sup>10</sup>)-O-C(O)-, -C(R<sup>9</sup>R<sup>10</sup>)-O-C(R<sup>9</sup>R<sup>10</sup>)-, -NR<sup>2</sup>-C(O)-C(R<sup>9</sup>R<sup>10</sup>)-, -O-C(O)-C(R<sup>9</sup>R<sup>10</sup>)-, -C(R<sup>9</sup>R<sup>10</sup>)-C(O)-NR<sup>2</sup>-, -C(R<sup>9</sup>R<sup>10</sup>)-C(O)-O-, -C(O)-NR<sup>2</sup>-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-, -C(O)-O-C(R<sup>9</sup>R<sup>10</sup>)-,
- 15 -C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-, -S(O)<sub>2</sub>-NR<sup>2</sup>-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-, -C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-NR<sup>2</sup>-C(O)-, -C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-O-C(O)-, -NR<sup>2</sup>-C(O)-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-, -NR<sup>2</sup>-S(O)<sub>2</sub>-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-, -O-C(O)-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-, -C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-C(O)-NR<sup>2</sup>-, -C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-C(O)-, -C(R<sup>9</sup>R<sup>10</sup>)-NR<sup>2</sup>-C(O)-O-, -C(R<sup>9</sup>R<sup>10</sup>)-O-C(O)-NR<sup>2</sup>,

- C(R<sup>9</sup>R<sup>10</sup>)-NR<sup>2</sup>-C(O)-NR<sup>2</sup>-, -NR<sup>2</sup>-C(O)-O-C(R<sup>9</sup>R<sup>10</sup>)-, -NR<sup>2</sup>-C(O)-NR<sup>2</sup>-C(R<sup>9</sup>R<sup>10</sup>)-, -NR<sup>2</sup>-S(O)<sub>2</sub>-NR<sup>2</sup>-C(R<sup>9</sup>R<sup>10</sup>)-, -O-C(O)-NR<sup>2</sup>-C(R<sup>9</sup>R<sup>10</sup>)-, -C(O)-N=C(R<sup>11</sup>)-NR<sup>2</sup>-, -C(O)-NR<sup>2</sup>-C(R<sup>11</sup>)=N-, -C(R<sup>9</sup>R<sup>10</sup>)-NR<sup>12</sup>-C(R<sup>9</sup>R<sup>10</sup>)-, -NR<sup>12</sup>-C(R<sup>9</sup>R<sup>10</sup>)-, -NR<sup>12</sup>-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-, -C(O)-O-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-, -NR<sup>2</sup>-C(R<sup>11</sup>)=N-C(O)-, -C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-N(R<sup>12</sup>)-, -C(R<sup>9</sup>R<sup>10</sup>)-NR<sup>12</sup>-, -N=C(R<sup>11</sup>)-NR<sup>2</sup>-C(O)-, -C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-NR<sup>2</sup>-S(O)<sub>2</sub>-, -C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-S(O)<sub>2</sub>-NR<sup>2</sup>-, -C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-C(O)-O-, -C(R<sup>9</sup>R<sup>10</sup>)-S(O)<sub>2</sub>-C(R<sup>9</sup>R<sup>10</sup>)-, -C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-S(O)<sub>2</sub>-, -O-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-, -C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)-O-, -C(R<sup>9</sup>R<sup>10</sup>)-C(O)-C(R<sup>9</sup>R<sup>10</sup>)-, -C(O)-C(R<sup>9</sup>R<sup>10</sup>)-C(R<sup>9</sup>R<sup>10</sup>)- and -C(R<sup>9</sup>R<sup>10</sup>)-NR<sup>2</sup>-S(O)<sub>2</sub>-NR<sup>2</sup>-;
- 10 Q is a covalent bond or CH<sub>2</sub>;  
W is CH or N;  
X is CR<sup>9</sup>R<sup>10</sup>, C=CH<sub>2</sub> or C=O;  
Y is CR<sup>9</sup>R<sup>10</sup>, O or NR<sup>2</sup>;  
Z is C=O, C=S or S(O)<sub>2</sub>;
- 15 G<sup>1</sup> is hydrogen, halo, hydroxy, nitro, amino, cyano, phenyl, carboxyl, -CONH<sub>2</sub>, -(C<sub>1</sub>-C<sub>4</sub>)alkyl optionally independently substituted with one or more phenyl, one or more halogens or one or more hydroxy groups, -(C<sub>1</sub>-C<sub>4</sub>)alkoxy optionally independently substituted with one or more phenyl, one or more halogens or one or more hydroxy groups, -(C<sub>1</sub>-C<sub>4</sub>)alkylthio, phenoxy, -COO(C<sub>1</sub>-C<sub>4</sub>)alkyl, N,N-di-(C<sub>1</sub>-C<sub>4</sub>)alkylamino, -(C<sub>2</sub>-C<sub>6</sub>)alkenyl optionally independently substituted with one or more phenyl, one or more halogens or one or more hydroxy groups, -(C<sub>2</sub>-C<sub>6</sub>)alkynyl optionally independently substituted with one or more phenyl, one or more halogens or one or more hydroxy groups, -(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl optionally independently substituted with one or more (C<sub>1</sub>-C<sub>4</sub>)alkyl groups, one or more halogens or one or more hydroxy groups, -(C<sub>1</sub>-C<sub>4</sub>)alkylamino carbonyl or di-(C<sub>1</sub>-C<sub>4</sub>)alkylamino carbonyl;
- 20 G<sup>2</sup> and G<sup>3</sup> are each independently selected from the group consisting of hydrogen, halo, hydroxy, -(C<sub>1</sub>-C<sub>4</sub>)alkyl optionally independently substituted with one to three halo groups and -(C<sub>1</sub>-C<sub>4</sub>)alkoxy optionally independently substituted with one to three halo groups;
- 25 R<sup>1</sup> is hydrogen, -CN, -(CH<sub>2</sub>)<sub>q</sub>N(X<sup>6</sup>)C(O)X<sup>6</sup>, -(CH<sub>2</sub>)<sub>q</sub>N(X<sup>6</sup>)C(O)(CH<sub>2</sub>)-A<sup>1</sup>, -(CH<sub>2</sub>)<sub>q</sub>N(X<sup>6</sup>)S(O)<sub>2</sub>(CH<sub>2</sub>)-A<sup>1</sup>, -(CH<sub>2</sub>)<sub>q</sub>N(X<sup>6</sup>)S(O)<sub>2</sub>X<sup>6</sup>, -(CH<sub>2</sub>)<sub>q</sub>N(X<sup>6</sup>)C(O)N(X<sup>6</sup>)(CH<sub>2</sub>)-A<sup>1</sup>, -(CH<sub>2</sub>)<sub>q</sub>N(X<sup>6</sup>)C(O)N(X<sup>6</sup>)(X<sup>6</sup>), -(CH<sub>2</sub>)<sub>q</sub>C(O)N(X<sup>6</sup>)(X<sup>6</sup>), -(CH<sub>2</sub>)<sub>q</sub>C(O)N(X<sup>6</sup>)(CH<sub>2</sub>)-A<sup>1</sup>, -(CH<sub>2</sub>)<sub>q</sub>C(O)OX<sup>6</sup>, -(CH<sub>2</sub>)<sub>q</sub>C(O)O(CH<sub>2</sub>)-A<sup>1</sup>, -(CH<sub>2</sub>)<sub>q</sub>OX<sup>6</sup>, -(CH<sub>2</sub>)<sub>q</sub>OC(O)X<sup>6</sup>, -(CH<sub>2</sub>)<sub>q</sub>OC(O)(CH<sub>2</sub>)-A<sup>1</sup>, -(CH<sub>2</sub>)<sub>q</sub>OC(O)N(X<sup>6</sup>)(CH<sub>2</sub>)-A<sup>1</sup>, -(CH<sub>2</sub>)<sub>q</sub>OC(O)N(X<sup>6</sup>)(X<sup>6</sup>),

$-(CH_2)_qC(O)X^6$ ,  $-(CH_2)_qC(O)(CH_2)_tA^1$ ,  $-(CH_2)_qN(X^6)C(O)OX^6$ ,  
 $-(CH_2)_qN(X^6)S(O)_2N(X^6)(X^6)$ ,  $-(CH_2)_qS(O)_mX^6$ ,  $-(CH_2)_qS(O)_m(CH_2)_tA^1$ ,  
 $-(C_1-C_{10})alkyl$ ,  $-(CH_2)_tA^1$ ,  $-(CH_2)_q-(C_3-C_7)cycloalkyl$ ,  $-(CH_2)_q-Y^1-(C_1-C_6)alkyl$ ,  
 $-(CH_2)_q-Y^1-(CH_2)_tA^1$  or  $-(CH_2)_q-Y^1-(CH_2)_t-(C_3-C_7)cycloalkyl$ ;

5 where the alkyl and cycloalkyl groups in the definition of  $R^1$  are optionally substituted with  $(C_1-C_4)alkyl$ , hydroxy,  $(C_1-C_4)alkoxy$ , carboxyl,  $-CONH_2$ ,  
 $-S(O)_m(C_1-C_6)alkyl$ ,  $-CO_2(C_1-C_4)alkyl$  ester, 1H-tetrazol-5-yl or 1, 2 or 3 fluoro groups;

10  $Y^1$  is O,  $S(O)_m$ ,  $-C(O)NX^6$ -,  $-CH=CH-$ ,  $-C\equiv C-$ ,  $-N(X^6)C(O)-$ ,  $-C(O)NX^6$ -,  
 $-C(O)O-$ ,  $-OC(O)N(X^6)-$  or  $-OC(O)-$ ;  
 q is 0, 1, 2, 3 or 4;

t is 0, 1, 2 or 3;

said  $(CH_2)_q$  group and  $(CH_2)_t$  group in the definition of  $R^1$  are optionally independently substituted with hydroxy,  $(C_1-C_4)alkoxy$ , carboxyl,  $-CONH_2$ ,

15  $-S(O)_m(C_1-C_6)alkyl$ ,  $-CO_2(C_1-C_4)alkyl$  ester, 1H-tetrazol-5-yl, 1, 2 or 3 fluoro groups or 1 or 2  $(C_1-C_4)alkyl$  groups;

$R^{1A}$  is selected from the group consisting of hydrogen, F, Cl, Br, I,  $(C_1-C_6)alkyl$ , phenyl $(C_1-C_3)alkyl$ , pyridyl $(C_1-C_3)alkyl$ , thiazolyl $(C_1-C_3)alkyl$  and thienyl $(C_1-C_3)alkyl$ , provided that  $R^{1A}$  is not F, Cl, Br or I when a heteroatom is vicinal to  $C^*$ ;

20  $R^2$  is hydrogen,  $(C_1-C_8)alkyl$ ,  $-(C_0-C_3)alkyl-(C_3-C_8)cycloalkyl$ ,  $-(C_1-C_4)alkyl-A^1$  or  $A^1$ ;  
 where the alkyl groups and the cycloalkyl groups in the definition of  $R^2$  are optionally substituted with hydroxy,  $-C(O)OX^6$ ,  $-C(O)N(X^6)(X^6)$ ,  $-N(X^6)(X^6)$ ,  $-S(O)_m(C_1-C_6)alkyl$ ,  $-C(O)A^1$ ,  $-C(O)(X^6)$ ,  $CF_3$ , CN or 1, 2 or 3 independently selected halo groups;


25  $R^3$  is selected from the group consisting of  $A^1$ ,  $(C_1-C_{10})alkyl$ ,  $-(C_1-C_6)alkyl-A^1$ ,  $-(C_1-C_6)alkyl-(C_3-C_7)cycloalkyl$ ,  $-(C_1-C_5)alkyl-X^1-(C_1-C_5)alkyl$ ,  $-(C_1-C_5)alkyl-X^1-(C_0-C_5)alkyl-A^1$  and  $-(C_1-C_5)alkyl-X^1-(C_1-C_5)alkyl-(C_3-C_7)cycloalkyl$ ;

where the alkyl groups in the definition of  $R^3$  are optionally substituted with  $-S(O)_m(C_1-C_6)alkyl$ ,  $-C(O)OX^3$ , 1, 2, 3, 4 or 5 independently selected halo groups or 1, 2 or 3 independently selected  $-OX^3$  groups;

30  $X^1$  is O,  $S(O)_m$ ,  $-N(X^2)C(O)-$ ,  $-C(O)N(X^2)-$ ,  $-OC(O)-$ ,  $-C(O)O-$ ,  $-CX^2=CX^2-$ ,  
 $-N(X^2)C(O)O-$ ,  $-OC(O)N(X^2)-$  or  $-C\equiv C-$ ;

$R^4$  is hydrogen,  $(C_1-C_6)alkyl$  or  $(C_3-C_7)cycloalkyl$ , or  $R^4$  is taken together with  $R^3$  and the carbon atom to which they are attached and form  $(C_5-C_7)cycloalkyl$ ,  $(C_5-$

C<sub>7</sub>)cycloalkenyl, a partially saturated or fully saturated 4- to 8-membered ring having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen, or is a bicyclic ring system consisting of a partially saturated or fully saturated 5- or 6-membered ring, fused to a partially saturated, fully unsaturated or fully saturated 5- or 6-membered ring, optionally having 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen; X<sup>4</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl or X<sup>4</sup> is taken together with R<sup>4</sup> and the nitrogen atom to which X<sup>4</sup> is attached and the carbon atom to which R<sup>4</sup> is attached and form a five to seven membered ring;



R<sup>6</sup> is a bond or is

where a and b are each independently 0, 1, 2 or 3;

X<sup>5</sup> and X<sup>5a</sup> are each independently selected from the group consisting of hydrogen, CF<sub>3</sub>, A<sup>1</sup> and optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl;

the optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl in the definition of X<sup>5</sup> and X<sup>5a</sup> is optionally substituted with a substituent selected from the group consisting of A<sup>1</sup>, OX<sup>2</sup>, -S(O)<sub>m</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, -C(O)OX<sup>2</sup>, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl, -N(X<sup>2</sup>)(X<sup>2</sup>) and -C(O)N(X<sup>2</sup>)(X<sup>2</sup>);

or the carbon bearing X<sup>5</sup> or X<sup>5a</sup> forms one or two alkylene bridges with the nitrogen atom bearing R<sup>7</sup> and R<sup>8</sup> wherein each alkylene bridge contains 1 to 5 carbon atoms, provided that when one alkylene bridge is formed then only one of X<sup>5</sup> or X<sup>5a</sup> is on the carbon atom and only one of R<sup>7</sup> or R<sup>8</sup> is on the nitrogen atom and further provided that when two alkylene bridges are formed then X<sup>5</sup> and X<sup>5a</sup> cannot be on the carbon atom and R<sup>7</sup> and R<sup>8</sup> cannot be on the nitrogen atom;


or X<sup>5</sup> is taken together with X<sup>5a</sup> and the carbon atom to which they are attached and form a partially saturated or fully saturated 3- to 7-membered ring, or a partially saturated or fully saturated 4- to 8-membered ring having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen;

or X<sup>5</sup> is taken together with X<sup>5a</sup> and the carbon atom to which they are attached and form a bicyclic ring system consisting of a partially saturated or

fully saturated 5- or 6-membered ring, optionally having 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen, fused to a partially saturated, fully saturated or fully unsaturated 5- or 6-membered ring, optionally having 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen;  
 $Z^1$  is a bond, O or  $N-X^2$ , provided that when a and b are both 0 then  $Z^1$  is not  $N-X^2$  or O;

or  $R^6$  is  $-(CR^aR^b)_a-E-(CR^aR^b)_b-$ , where the  $-(CR^aR^b)_a-$  group is attached to the carbonyl carbon of the amide group of the compound of formula I and the  $-(CR^aR^b)_b$  group is attached to the terminal nitrogen atom of the compound of formula I;

E is -O-, -S-, -CH=CH- or an aromatic moiety selected from



said aromatic moiety in the definition of E optionally substituted with up to three halo, hydroxy,  $-N(R^c)(R^c)$ ,  $(C_1-C_6)$ alkyl or  $(C_1-C_6)$ alkoxy;

$R^a$  and  $R^b$  are, for each occurrence, independently hydrogen,  $(C_1-C_6)$ alkyl, trifluoromethyl, phenyl or monosubstituted  $(C_1-C_6)$ alkyl where the substituents are imidazolyl, naphthyl, phenyl, indolyl, p-hydroxyphenyl,  $-OR^c$ ,  $S(O)_mR^c$ ,  $C(O)OR^c$ ,  $(C_3-C_7)$ cycloalkyl,  $-N(R^c)(R^c)$ ,  $-C(O)N(R^c)(R^c)$ , or  $R^a$  or  $R^b$  may independently be joined to one or both of  $R^7$  or E (where E is other than O, S or -CH=CH-) to form an alkylene bridge between the terminal nitrogen and the alkyl portion of the  $R^a$  or  $R^b$  and the  $R^7$  or E group, wherein the bridge contains 1 to 8 carbon atoms; or  $R^a$  and  $R^b$  may be joined to one another to form a  $(C_3-C_7)$ cycloalkyl;

$R^c$ , for each occurrence, is independently hydrogen or  $(C_1-C_6)$ alkyl;

a and b are independently 0, 1, 2 or 3, with the proviso that if E is -O- or -S-, b is other than 0 or 1 and with the further proviso that if E is -CH=CH-, b is other than 0;

$R^7$  and  $R^8$  are each independently hydrogen or optionally substituted  $(C_1-C_6)$ alkyl;

where the optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl in the definition of R<sup>7</sup> and R<sup>8</sup> is optionally independently substituted with A<sup>1</sup>, -C(O)O-(C<sub>1</sub>-C<sub>6</sub>)alkyl,

-S(O)<sub>m</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, 1 to 5 halo groups, 1 to 3 hydroxy groups, 1 to 3

-O-C(O)(C<sub>1</sub>-C<sub>10</sub>)alkyl groups or 1 to 3 (C<sub>1</sub>-C<sub>6</sub>)alkoxy groups; or

- 5 R<sup>7</sup> and R<sup>8</sup> can be taken together to form -(CH<sub>2</sub>)<sub>r</sub>-L-(CH<sub>2</sub>)<sub>r</sub>;

where L is C(X<sup>2</sup>)(X<sup>2</sup>), S(O)<sub>m</sub> or N(X<sup>2</sup>);

R<sup>9</sup> and R<sup>10</sup> are each independently selected from the group consisting of hydrogen, fluoro, hydroxy and (C<sub>1</sub>-C<sub>5</sub>)alkyl optionally independently substituted with 1-5 halo groups;

- 10 R<sup>11</sup> is selected from the group consisting of (C<sub>1</sub>-C<sub>5</sub>)alkyl and phenyl optionally substituted with 1-3 substituents each independently selected from the group consisting of (C<sub>1</sub>-C<sub>5</sub>)alkyl, halo and (C<sub>1</sub>-C<sub>5</sub>)alkoxy;

R<sup>12</sup> is selected from the group consisting of (C<sub>1</sub>-C<sub>5</sub>)alkylsulfonyl, (C<sub>1</sub>-C<sub>5</sub>)alkanoyl and (C<sub>1</sub>-C<sub>5</sub>)alkyl where the alkyl portion is optionally independently substituted by 1-5 halo groups;

- 15 A<sup>1</sup> for each occurrence is independently selected from the group consisting of (C<sub>5</sub>-C<sub>7</sub>)cycloalkenyl, phenyl, a partially saturated, fully saturated or fully unsaturated 4- to 8-membered ring optionally having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen and a bicyclic ring system consisting of a partially saturated, fully unsaturated or fully saturated 5- or 6-membered ring, optionally having 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen, fused to a partially saturated, fully saturated or fully unsaturated 5- or 6-membered ring, optionally having 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen;

A<sup>1</sup> for each occurrence is independently optionally substituted, on one or optionally both rings if A<sup>1</sup> is a bicyclic ring system, with up to three substituents, each substituent independently selected from the group consisting of F, Cl, Br, I, OCF<sub>3</sub>, OCF<sub>2</sub>H, CF<sub>3</sub>, CH<sub>3</sub>, OCH<sub>3</sub>, -OX<sup>6</sup>,

- 30 -C(O)N(X<sup>6</sup>)(X<sup>6</sup>), -C(O)OX<sup>6</sup>, oxo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, nitro, cyano, benzyl, -S(O)<sub>m</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, 1H-tetrazol-5-yl, phenyl, phenoxy, phenylalkyloxy, halophenyl, methylenedioxy, -N(X<sup>6</sup>)(X<sup>6</sup>), -N(X<sup>6</sup>)C(O)(X<sup>6</sup>), -S(O)<sub>2</sub>N(X<sup>6</sup>)(X<sup>6</sup>), -N(X<sup>6</sup>)S(O)<sub>2</sub>-phenyl, -N(X<sup>6</sup>)S(O)<sub>2</sub>X<sup>6</sup>, -CONX<sup>11</sup>X<sup>12</sup>, -S(O)<sub>2</sub>NX<sup>11</sup>X<sup>12</sup>,



$-NX^6S(O)_2X^{12}$ ,  $-NX^6CONX^{11}X^{12}$ ,  $-NX^6S(O)_2NX^{11}X^{12}$ ,  $-NX^6C(O)X^{12}$ , imidazolyl, thiazolyl and tetrazolyl, provided that if  $A^1$  is optionally substituted with methylenedioxy then it can only be substituted with one methylenedioxy;

where  $X^{11}$  is hydrogen or optionally substituted  $(C_1-C_6)$ alkyl;

the optionally substituted  $(C_1-C_6)$ alkyl defined for  $X^{11}$  is optionally independently substituted with phenyl, phenoxy,  $(C_1-C_6)$ alkoxycarbonyl,  $-S(O)_m(C_1-C_6)$ alkyl, 1 to 5 halo groups, 1 to 3 hydroxy groups, 1 to 3  $(C_1-C_{10})$ alkanoyloxy groups or 1 to 3  $(C_1-C_6)$ alkoxy groups;

$X^{12}$  is hydrogen,  $(C_1-C_6)$ alkyl, phenyl, thiazolyl, imidazolyl, furyl or thienyl, provided that when  $X^{12}$  is not hydrogen, the  $X^{12}$  group is optionally substituted with one to three substituents independently selected from the group consisting of Cl, F,  $CH_3$ ,  $OCH_3$ ,  $OCF_3$  and  $CF_3$ ;

or  $X^{11}$  and  $X^{12}$  are taken together to form  $-(CH_2)_r-L^1-(CH_2)_r-$ ;

$L^1$  is  $C(X^2)(X^2)$ , O,  $S(O)_m$  or  $N(X^2)$ ;

r for each occurrence is independently 1, 2 or 3;

$X^2$  for each occurrence is independently hydrogen, optionally substituted  $(C_1-C_6)$ alkyl or optionally substituted  $(C_3-C_7)$ cycloalkyl, where the optionally substituted  $(C_1-C_6)$ alkyl and optionally substituted  $(C_3-C_7)$ cycloalkyl in the definition of  $X^2$  are optionally independently substituted with  $-S(O)_m(C_1-C_6)$ alkyl,  $-C(O)OX^3$ , 1 to 5 halo groups or 1-3  $OX^3$  groups;

$X^3$  for each occurrence is independently hydrogen or  $(C_1-C_6)$ alkyl;

$X^6$  for each occurrence is independently hydrogen, optionally substituted  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ halogenated alkyl, optionally substituted  $(C_3-C_7)$ cycloalkyl,  $(C_3-C_7)$ -halogenated cycloalkyl, where optionally substituted  $(C_1-C_6)$ alkyl and optionally substituted  $(C_3-C_7)$ cycloalkyl in the definition of  $X^6$  is optionally independently mono- or di-substituted with  $(C_1-C_4)$ alkyl, hydroxy,  $(C_1-C_4)$ alkoxy, carboxyl,  $CONH_2$ ,  $-S(O)_m(C_1-C_6)$ alkyl, carboxylate  $(C_1-C_4)$ alkyl ester or 1H-tetrazol-5-yl; or


when there are two  $X^6$  groups on one atom and both  $X^6$  are independently  $(C_1-C_6)$ alkyl, the two  $(C_1-C_6)$ alkyl groups may be optionally joined and, together with the atom to which the two  $X^6$  groups are attached, form a 4- to 9- membered ring optionally having oxygen, sulfur or  $NX^7$  as a ring member;

$X^7$  is hydrogen or  $(C_1-C_6)$ alkyl optionally substituted with hydroxy;

m for each occurrence is independently 0, 1 or 2;

with the provisos that:

- 1)  $X^6$  and  $X^{12}$  cannot be hydrogen when attached to  $C(O)$  or  $S(O)_2$  in the form  $C(O)X^6$ ,  $C(O)X^{12}$ ,  $S(O)_2X^6$  or  $S(O)_2X^{12}$ ; and
- 2) when  $R^6$  is a bond then L is  $N(X^2)$  and each r in the definition  $-(CH_2)_r-L-(CH_2)_r-$  is independently 2 or 3. It is preferred that the GHS is a compound of the formula



or a racemic-diastereomeric mixture or an optical isomer of said compound or a pharmaceutically-acceptable salt or prodrug thereof,

10 wherein

f is 0;

n is 0 and w is 2, or n is 1 and w is 1, or n is 2 and w is 0;

Y is oxygen or sulfur;

- 15  $R^1$  is hydrogen,  $-CN$ ,  $-(CH_2)_qN(X^6)C(O)X^6$ ,  $-(CH_2)_qN(X^6)C(O)(CH_2)_rA^1$ ,  $-(CH_2)_qN(X^6)SO_2(CH_2)_rA^1$ ,  $-(CH_2)_qN(X^6)SO_2X^6$ ,  $-(CH_2)_qN(X^6)C(O)N(X^6)(CH_2)_rA^1$ ,  $-(CH_2)_qN(X^6)C(O)N(X^6)(X^6)$ ,  $-(CH_2)_qC(O)N(X^6)(X^6)$ ,  $-(CH_2)_qC(O)N(X^6)(CH_2)_rA^1$ ,  $-(CH_2)_qC(O)OX^6$ ,  $-(CH_2)_qC(O)O(CH_2)_rA^1$ ,  $-(CH_2)_qOX^6$ ,  $-(CH_2)_qOC(O)X^6$ ,  $-(CH_2)_qOC(O)(CH_2)_rA^1$ ,  $-(CH_2)_qOC(O)N(X^6)(CH_2)_rA^1$ ,  $-(CH_2)_qOC(O)N(X^6)(X^6)$ ,  $-(CH_2)_qC(O)X^6$ ,  $-(CH_2)_qC(O)(CH_2)_rA^1$ ,  $-(CH_2)_qN(X^6)C(O)OX^6$ ,
- 20  $-(CH_2)_qN(X^6)SO_2N(X^6)(X^6)$ ,  $-(CH_2)_qS(O)_mX^6$ ,  $-(CH_2)_qS(O)_m(CH_2)_rA^1$ ,  $-(C_1-C_{10})$ alkyl,  $-(CH_2)_rA^1$ ,  $-(CH_2)_q-(C_3-C_7)$ cycloalkyl,  $-(CH_2)_q-Y^1-(C_1-C_6)$ alkyl,  $-(CH_2)_q-Y^1-(CH_2)_rA^1$  or  $-(CH_2)_q-Y^1-(CH_2)_r-(C_3-C_7)$ cycloalkyl;

where the alkyl and cycloalkyl groups in the definition of  $R^1$  are optionally substituted with  $(C_1-C_4)$ alkyl, hydroxyl,  $(C_1-C_4)$ alkoxy, carboxyl,  $-CONH_2$ ,

25  $-S(O)_m(C_1-C_6)$ alkyl,  $-CO_2(C_1-C_4)$ alkyl ester, 1H-tetrazol-5-yl or 1, 2 or 3 fluoro;

$Y^1$  is O,  $S(O)_m$ ,  $-C(O)NX^6$ ,  $-CH=CH-$ ,  $-C\equiv C-$ ,  $-N(X^6)C(O)-$ ,  $-C(O)NX^6$ ,  $-C(O)O-$ ,  $-OC(O)N(X^6)-$  or  $-OC(O)-$ ;

q is 0, 1, 2, 3 or 4;

t is 0, 1, 2 or 3;

said  $(CH_2)_q$  group and  $(CH_2)_l$  group may each be optionally substituted with hydroxyl,  $(C_1-C_4)$ alkoxy, carboxyl,  $-CONH_2$ ,  $-S(O)_m(C_1-C_6)$ alkyl,

$-CO_2(C_1-C_4)$ alkyl ester, 1H-tetrazol-5-yl, 1, 2 or 3 fluoro, or 1 or 2  $(C_1-C_4)$ alkyl;

$R^2$  is hydrogen,  $(C_1-C_8)$ alkyl,  $-(C_0-C_3)$ alkyl- $(C_3-C_6)$ cycloalkyl,  $-(C_1-C_4)$ alkyl- $A^1$  or  $A^1$ ;

5 where the alkyl groups and the cycloalkyl groups in the definition of  $R^2$  are optionally substituted with hydroxyl,  $-C(O)OX^6$ ,  $-C(O)N(X^6)(X^6)$ ,  $-N(X^6)(X^6)$ ,  $-S(O)_m(C_1-C_6)$ alkyl,  $-C(O)A^1$ ,  $-C(O)(X^6)$ ,  $CF_3$ , CN or 1, 2 or 3 halogen;

$R^3$  is  $A^1$ ,  $(C_1-C_{10})$ alkyl,  $-(C_1-C_6)$ alkyl- $A^1$ ,  $-(C_1-C_6)$ alkyl- $(C_3-C_7)$ cycloalkyl,

10  $-(C_1-C_5)$ alkyl- $X^1$ -( $C_1-C_5$ )alkyl,  $-(C_1-C_5)$ alkyl- $X^1$ -( $C_0-C_5$ )alkyl- $A^1$  or

$-(C_1-C_5)$ alkyl- $X^1$ -( $C_1-C_5$ )alkyl- $(C_3-C_7)$ cycloalkyl;

where the alkyl groups in the definition of  $R^3$  are optionally substituted with,


$-S(O)_m(C_1-C_6)$ alkyl,  $-C(O)OX^3$ , 1, 2, 3, 4 or 5 halogens, or 1, 2 or 3  $OX^3$ ;

$X^1$  is O,  $S(O)_m$ ,  $-N(X^2)C(O)-$ ,  $-C(O)N(X^2)-$ ,  $-OC(O)-$ ,  $-C(O)O-$ ,  $-CX^2=CX^2-$ ,

15  $-N(X^2)C(O)O-$ ,  $-OC(O)N(X^2)-$  or  $-C\equiv C-$ ;

$R^4$  is hydrogen,  $(C_1-C_6)$ alkyl or  $(C_3-C_7)$ cycloalkyl;

$X^4$  is hydrogen or  $(C_1-C_6)$ alkyl or  $X^4$  is taken together with  $R^4$  and the nitrogen atom to which  $X^4$  is attached and the carbon atom to which  $R^4$  is attached and form a five to seven membered ring;



20  $R^6$  is a bond or is

where a and b are independently 0, 1, 2 or 3;

$X^5$  and  $X^{5a}$  are each independently selected from the group consisting of hydrogen, trifluoromethyl,  $A^1$  and optionally substituted  $(C_1-C_6)$ alkyl;

the optionally substituted  $(C_1-C_6)$ alkyl in the definition of  $X^5$  and  $X^{5a}$  is

25 optionally substituted with a substituent selected from the group consisting of  $A^1$ ,  $OX^2$ ,  $-S(O)_m(C_1-C_6)$ alkyl,  $-C(O)OX^2$ ,  $(C_3-C_7)$ cycloalkyl,  $-N(X^2)(X^2)$  and  $-C(O)N(X^2)(X^2)$ ;

$R^7$  and  $R^8$  are independently hydrogen or optionally substituted  $(C_1-C_6)$ alkyl;

where the optionally substituted  $(C_1-C_6)$ alkyl in the definition of  $R^7$  and  $R^8$  is

30 optionally independently substituted with  $A^1$ ,  $-C(O)O-(C_1-C_6)$ alkyl,

$-S(O)_m(C_1-C_6)alkyl$ , 1 to 5 halogens, 1 to 3 hydroxy, 1 to 3  $-O-C(O)(C_1-C_{10})alkyl$  or 1 to 3  $(C_1-C_6)alkoxy$ ; or

$R^7$  and  $R^8$  can be taken together to form  $-(CH_2)_r-L-(CH_2)_r-$ ;

where L is  $C(X^2)(X^2)$ ,  $S(O)_m$  or  $N(X^2)$ ;

- 5  $A^1$  in the definition of  $R^1$  is a partially saturated, fully saturated or fully unsaturated 4- to 8-membered ring optionally having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen, a bicyclic ring system consisting of a partially saturated, fully unsaturated or fully saturated 5- or 6-membered ring, having 1 to 4 heteroatoms independently selected from the group consisting of
- 10 nitrogen, sulfur and oxygen, fused to a partially saturated, fully saturated or fully unsaturated 5- or 6-membered ring, optionally having 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen;
- $A^1$  in the definition of  $R^2$ ,  $R^3$ ,  $R^6$ ,  $R^7$  and  $R^8$  is independently  $(C_5-C_7)cycloalkenyl$ , phenyl or a partially saturated, fully saturated or fully unsaturated 4- to 8- membered
- 15 ring optionally having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen, a bicyclic ring system consisting of a partially saturated, fully unsaturated or fully saturated 5- or 6- membered ring, optionally having 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen, fused to a partially saturated, fully saturated
- 20 or fully unsaturated 5- or 6- membered ring, optionally having 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen;

- $A^1$  for each occurrence is independently optionally substituted, in one or optionally both rings if  $A^1$  is a bicyclic ring system, with up to three substituents, each substituent independently selected from the group
- 25 consisting of F, Cl, Br, I,  $OCF_3$ ,  $OCF_2H$ ,  $CF_3$ ,  $CH_3$ ,  $OCH_3$ ,  $-OX^6$ ,  $-C(O)N(X^6)(X^6)$ ,  $-C(O)OX^6$ , oxo,  $(C_1-C_6)alkyl$ , nitro, cyano, benzyl,  $-S(O)_m(C_1-C_6)alkyl$ , 1H-tetrazol-5-yl, phenyl, phenoxy, phenylalkyloxy, halophenyl, methylenedioxy,  $-N(X^6)(X^6)$ ,  $-N(X^6)C(O)(X^6)$ ,  $-SO_2N(X^6)(X^6)$ ,  $-N(X^6)SO_2-phenyl$ ,  $-N(X^6)SO_2X^6$ ,  $-CONX^{11}X^{12}$ ,  $-SO_2NX^{11}X^{12}$ ,  $-NX^6SO_2X^{12}$ ,
- 30  $-NX^6CONX^{11}X^{12}$ ,  $-NX^6SO_2NX^{11}X^{12}$ ,  $-NX^6C(O)X^{12}$ , imidazolyl, thiazolyl or tetrazolyl, provided that if  $A^1$  is optionally substituted with methylenedioxy then it can only be substituted with one methylenedioxy;

where  $X^{11}$  is hydrogen or optionally substituted  $(C_1-C_6)alkyl$ ;

the optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl defined for X<sup>11</sup> is optionally independently substituted with phenyl, phenoxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl, -S(O)<sub>m</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl 1 to 5 halogens, 1 to 3 hydroxy, 1 to 3 (C<sub>1</sub>-C<sub>10</sub>)alkanoyloxy or 1 to 3 (C<sub>1</sub>-C<sub>6</sub>)alkoxy;

X<sup>12</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, phenyl, thiazolyl, imidazolyl, furyl or thienyl, provided that when X<sup>12</sup> is not hydrogen, X<sup>12</sup> is optionally substituted with one to three substituents independently selected from the group consisting of Cl, F, CH<sub>3</sub>, OCH<sub>3</sub>, OCF<sub>3</sub> and CF<sub>3</sub>;

or X<sup>11</sup> and X<sup>12</sup> are taken together to form -(CH<sub>2</sub>)<sub>r</sub>-L<sup>1</sup>-(CH<sub>2</sub>)<sub>r</sub>;

where L<sup>1</sup> is C(X<sup>2</sup>)(X<sup>2</sup>), O, S(O)<sub>m</sub> or N(X<sup>2</sup>);

r for each occurrence is independently 1, 2 or 3;

X<sup>2</sup> for each occurrence is independently hydrogen, optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, or optionally substituted (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl, where the optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl and optionally substituted (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl in the definition of X<sup>2</sup> are optionally independently substituted with -S(O)<sub>m</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, -C(O)OX<sup>3</sup>, 1 to 5 halogens or 1-3 OX<sup>3</sup>;

X<sup>3</sup> for each occurrence is independently hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

X<sup>6</sup> is independently hydrogen, optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)halogenated alkyl, optionally substituted (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-halogenatedcycloalkyl, where optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl and optionally substituted (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl in the definition of X<sup>6</sup> is optionally independently substituted by 1 or 2 (C<sub>1</sub>-C<sub>4</sub>)alkyl, hydroxyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, carboxyl, CONH<sub>2</sub>, -S(O)<sub>m</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, carboxylate (C<sub>1</sub>-C<sub>4</sub>)alkyl ester, or 1H-tetrazol-5-yl; or

when there are two X<sup>6</sup> groups on one atom and both X<sup>6</sup> are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl, the two (C<sub>1</sub>-C<sub>6</sub>)alkyl groups may be optionally joined and, together with the atom to which the two X<sup>6</sup> groups are attached, form a 4- to 9- membered ring optionally having oxygen, sulfur or NX<sup>7</sup>;

X<sup>7</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with hydroxyl; and

m for each occurrence is independently 0, 1 or 2;

with the proviso that:

X<sup>6</sup> and X<sup>12</sup> cannot be hydrogen when it is attached to C(O) or SO<sub>2</sub> in the form C(O)X<sup>6</sup>, C(O)X<sup>12</sup>, SO<sub>2</sub>X<sup>6</sup> or SO<sub>2</sub>X<sup>12</sup>; and

when R<sup>6</sup> is a bond then L is N(X<sup>2</sup>) and each r in the definition -(CH<sub>2</sub>)<sub>r</sub>-L-(CH<sub>2</sub>)<sub>r</sub>- is independently 2 or 3.

In the combinations, pharmaceutical compositions, methods and kits of this invention, it is even more preferred that said GHS is 2-amino-N-(1(R)-benzyloxymethyl-2-(1,3-dioxo-8a(S)-pyridin-2-ylmethyl-2-(2,2,2-trifluoro-ethyl)-hexahydro-imidazo[1,5-a]pyrazin-7-yl]-2-oxo-ethyl)-2-methyl-propionamide; 2-amino-N-[2-(3a(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide; or 2-amino-N-(1-(R)-(2,4-difluoro-benzyloxymethyl)-2-oxo-2-(3-oxo-3a(R)-pyridin-2-ylmethyl)-2-(2,2,2-trifluoro-ethyl)-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-ethyl)-2-methyl-propionamide, or a prodrug thereof or a pharmaceutically acceptable salt thereof or of said prodrug.

In the combinations, pharmaceutical compositions, methods and kits of this invention, it is still more especially preferred that the L-tartrate salt of 2-amino-N-(1(R)-benzyloxymethyl-2-(1,3-dioxo-8a(S)-pyridin-2-ylmethyl-2-(2,2,2-trifluoro-ethyl)-hexahydro-imidazo[1,5-a]pyrazin-7-yl]-2-oxo-ethyl)-2-methyl-propionamide; the L-tartrate salt of 2-amino-N-(2-(3a(R)-benzyl-2-methyl-3-oxo-2,3, 3a, 4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1(R)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide; or the L-tartrate salt of 2-amino-N-(1-(R)-(2,4-difluoro-benzyloxymethyl)-2-oxo-2-(3-oxo-3a(R)-pyridin-2-yl)-2-(2,2,2-trifluoro-ethyl)-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-ethyl)-2-methyl-propionamide is used.

This invention is also directed to methods comprising administering a recombinant growth hormone or an additional GHS selected from the group consisting of GHRP-6, GHRP-1, GHRP-2, growth hormone releasing factor and an analog of growth hormone releasing factor in addition to said GHS.

In the combinations of this invention it is preferred that said glucocorticoid is prednisone, betamethasone dipropionate, clobetasol, diflorasone diacetate, halobetasol propionate, amcinonide, desoximetasone, fluocinonide, halcinonide, betamethasone valerate, triamcinolone acetate, fluocinolone acetonide, flurandrenolide, hydrocortisone valerate, triamcinolone acetonide, hydrocortisone butyrate, alclometasone dipropionate, desonide, mometasone furoate, dexamethasone, hydrocortisone or methylprednisolone acetate. Also preferred in this invention are combinations wherein said antimalarial is chloroquine, hydroxychloroquine, quinacrine or quinine.

The term "pharmaceutically acceptable" means that a substance or mixture of substances must be compatible with the other ingredients of a formulation and not deleterious to a patient.

5 The term "treating", "treat" or "treatment" as used herein includes curative, preventative (e.g., prophylactic) and palliative treatment.

The terms "patient" and "subject" are used interchangeably and refer to animals, particularly mammals such as dogs, cats, cattle, horses, sheep and humans. Particularly preferred patients and subjects are humans, including males and females.

10 The term "therapeutically effective amount" means an amount of a GHS that ameliorates, attenuates, or eliminates a particular disease or condition associated with growth hormone secretion and/or production, or prevents or delays the onset of a disease or condition associated with growth hormone secretion and/or production.

15 The parenthetical negative or positive sign used herein in the nomenclature denotes the direction plane polarized light is rotated by the particular stereoisomer.

The subject invention also includes combinations, pharmaceutical compositions, methods and kits comprising isotopically-labeled compounds, which are identical to the compounds described hereinabove, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds used in the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as  $^2\text{H}$ ,  $^3\text{H}$ ,  $^{13}\text{C}$ ,  $^{14}\text{C}$ ,  $^{15}\text{N}$ ,  $^{18}\text{O}$ ,  $^{17}\text{O}$ ,  $^{31}\text{P}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{18}\text{F}$  and  $^{36}\text{Cl}$ , respectively. Compounds used in the present invention, prodrugs thereof, and  
25 pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as  $^3\text{H}$  and  $^{14}\text{C}$  are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e.,  $^3\text{H}$ , and carbon-14, i.e.,  $^{14}\text{C}$ , isotopes are particularly preferred for their ease of  
30 preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e.,  $^2\text{H}$ , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically

labeled compounds used in this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and /or in the Examples and Preparations described in the patents and applications which are incorporated herein by reference, by substituting a readily available isotopically  
5 labeled reagent for a non-isotopically labeled reagent.

Other features and advantages will be apparent from the description and claims which describe the invention.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to the use of a compound, which has the  
10 ability to stimulate or amplify the release of natural or endogenous growth hormone, for treating systemic lupus erythematosus. In particular, the present invention provides a method for treating systemic lupus erythematosus comprising the administration of a GHS, a prodrug thereof or a pharmaceutically acceptable salt of said GHS or of said prodrug. The present invention also provides a method for  
15 treating IBD such as Crohn's disease or ulcerative colitis comprising the administration of a GHS, a prodrug thereof or a pharmaceutically acceptable salt of said GHS or of said prodrug.

By the term "growth hormone secretagogue" is meant any exogenously administered compound or agent that directly or indirectly stimulates or increases the  
20 endogenous release of growth hormone, growth hormone-releasing hormone or somatostatin in an animal, in particular, a human.


In the treatment of systemic lupus erythematosus, the GHS may be used alone or in combination with other GHSs or with other agents which are known to be beneficial for the treatment of systemic lupus erythematosus. The GHS and the other  
25 agent may be coadministered, either in concomitant therapy or in a fixed combination. For example, the GHS may be administered in combination with methotrexate, dapsone, a glucocorticoid or an antimalarial.

In the treatment of IBD such as Crohn's disease or ulcerative colitis, the GHS may be used alone or in combination with other GHSs or with other agents which are  
30 known to be beneficial for the treatment of IBD such as Crohn's disease or ulcerative colitis. The GHS and the other agent may be coadministered, either in concomitant therapy or in a fixed combination. For example, the GHS may be administered in combination with prednisone, sulfasalazine, mesalamine or olsalazine.




Representative GHSs and a full description of procedures for preparing those GHSs, are disclosed in the following International Patent Applications (listed by Publication Nos.), issued U.S. patents and published European patent applications, each of which is incorporated herein by reference: WO 98/46569, WO 98/51687, WO 96/38471, WO 96/35713, WO 98/58947, WO 98/58949, WO 98/58950, WO 99/08697, WO 99/09991, WO 95/13069, U.S. 5,492,916, U.S. 5,494,919, WO 95/14666, WO 94/19367, WO 94/13696, WO 94/11012, U.S. 5,726,319, WO 95/11029, WO 95/17422, WO 95/17423, WO 95/34311, WO 96/02530, WO 96/22996, WO 96/22997, WO 96/24580, WO 96/24587, U.S. 5,559,128, WO 96/32943, WO 96/33189, WO 96/15148, WO 97/00894, WO 97/07117, WO 97/06803, WO 97/11697, WO 97/15573, WO 97/22367, WO 97/23508, WO 97/22620, WO 97/22004, WO 97/21730, WO 97/24369, U.S. 5,663,171, WO 97/34604, WO 97/36873, WO 97/40071, WO 97/40023, WO 97/41878, WO97/41879, WO 97/46252, WO 97/44042, WO 97/38709, WO 98/03473, WO 97/43278, U.S. 5,721,251, U.S. 5,721,250, WO 98/10653, U.S. 5,919,777, U.S. 5,830,433 and EP 0995748.

A representative first group of GHSs is set forth in International Patent Application, Publication No. WO 97/24369, as compounds having the structural formula below, which is designated herein as Formula II:




wherein the various substituents are as defined in WO 97/24369. Said compounds are prepared as disclosed therein.

2-Amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide, having the following structure:



and 2-amino-N-(1-(R)-(2,4-difluoro-benzyloxymethyl)-2-oxo-2-(3-oxo-3a(R)-pyridin-2-ylmethyl)-2-(2,2,2-trifluoro-ethyl)-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-ethyl)-2-methyl-propionamide, having the following structure:




5

are both within the scope of the disclosure of International Patent Application, Publication Number WO 97/24369.

A representative second group of GHSs is set forth in International Patent Application, Publication No. WO 98/58947, as compounds having the structural formula below, which is designated herein as Formula III:


10



III

wherein the various substituents are as defined in WO 98/58947. Said compounds are prepared as disclosed therein or as described herein.


A preferred compound within this second group which may be employed in the present invention is identified as having the following name and structure: 2-amino-N-(1(R)-benzyloxymethyl-2-(1,3-dioxo-8a(S)-pyridin-2-ylmethyl-2-(2,2,2-trifluoro-ethyl)-hexahydro-imidazo[1,5-a]pyrazin-7-yl)-2-oxo-ethyl)-2-methyl-propionamide,



This compound is within the scope of the disclosure of International Patent Application, Publication No. WO 98/58947, and may be prepared as described in Examples Five and Six therein.


A representative third group of GHSs is set forth in Published European patent application 0995748, which discloses certain dipeptide GHSs of Formula III, as designated above, and their use for the treatment or prevention of musculoskeletal frailty including osteoporosis.

A representative fourth group of GHSs is set forth in U.S. Patent No. 5,206,235, as having the following structure:




wherein the various substituents are as defined in U.S. Patent No. 5,206,235. Said compounds are prepared as disclosed therein.

Preferred compounds within this fourth group are identified as having the following structures:




or




5

A representative fifth group of GHSs is set forth in U.S. Patent No. 5,283,241, as having the following structural formula:




wherein the various substituents are as defined in U.S. Patent 5,283,241. Said compounds are prepared as disclosed therein.

A representative sixth group of GHSs is disclosed in International Patent Application, Publication No. WO 97/41879, as compounds having the following structural formulas:




wherein the various substituents are as defined in WO97/41879. Said compounds are prepared as disclosed therein.

Preferred compounds within this sixth group which may be employed in the present invention are identified as having the following structure:



and pharmaceutically acceptable salts thereof, in particular, the methanesulfonate salt.

A representative seventh group of GHSs is disclosed in U.S. Patent No. 5,492,916, as being compounds of the following structural formula:



wherein the various substituents are as defined in U.S. Patent No. 5,492,916. Said compounds are prepared as disclosed therein.

All of these compounds may be prepared by procedures disclosed in these publications. Full descriptions of the preparation of the GHSs which may be employed in the present invention may be found in the art, particularly in the references cited herein.

As set forth hereinabove, a second therapeutic agent may be used in conjunction with the GHS in the combinations, pharmaceutical compositions, kits and methods of this invention. When the second therapeutic agent is a glucocorticoid, suitable glucocorticoids are prednisone, betamethasone dipropionate, clobetasol, diflorasone diacetate, halobetasol propionate, amcinonide, desoximetasone, fluocinonide, halcinonide, betamethasone valerate, triamcinolone acetate, fluocinolone acetonide, flurandrenolide, hydrocortisone valerate, triamcinolone acetonide, hydrocortisone butyrate, alclometasone dipropionate, desonide, mometasone furoate, dexamethasone, hydrocortisone or methylprednisolone acetate. Other glucocorticoids are also within the scope of the combinations of this invention.

When the second therapeutic agent is an antimalarial, suitable antimalarials include quinine, chloroquine, quinacrine and hydroxychloroquine. Other antimalarial agents are also within the scope of the combinations, pharmaceutical compositions, kits and methods of this invention.

The second therapeutic agents set forth herein, including methotrexate, dapsone, the glucocorticoids disclosed herein and the antimalarials disclosed herein, are all readily available or can be prepared as set forth in references which may be found in the Merck Index, 12<sup>th</sup> Edition, Merck & Co., Whitehouse Station, New Jersey, 1996.

Mesalamine, also known as 5-amino-2-hydroxybenzoic acid, is prepared from 2-hydroxy-5-nitrobenzoic acid (Aldrich Chemical Company, P.O. Box 355, Milwaukee, Wisconsin 52301-9358) by reduction methods well known to those skilled in the art. A particularly useful process for effecting said reduction is by reacting said 2-hydroxy-5-nitrobenzoic acid with zinc dust and hydrochloric acid as described by Weil et al., Ber. **55B**, 2664 (1922).

Sulfasalazine may be prepared as described in United States Patent Number 2,396,145.

Olsalazine may be prepared as described in United States Patent Number 4,528,367.

Prednisone may be prepared as described in United States Patent Numbers 2,897,216; 2,837,464; or 3,134,718; or as described in Herzog et al., Tetrahedron, **18**, 581 (1962) or Nobile et al., JACS, **77**, 4184 (1955).

The expression "pharmaceutically acceptable salts" includes both pharmaceutically acceptable acid addition salts and pharmaceutically acceptable cationic salts, where appropriate. The expression "pharmaceutically-acceptable cationic salts" is intended to define but is not limited to such salts as the alkali metal salts, (e.g., sodium and potassium), alkaline earth metal salts (e.g., calcium and magnesium), aluminum salts, ammonium salts, and salts with organic amines such as benzathine (N,N'-dibenzylethylenediamine), choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), benethamine (N-benzylphenethylamine), diethylamine, piperazine, tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol) and procaine. The expression "pharmaceutically-acceptable acid addition salts" is intended to define but is not limited to such salts as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogenphosphate, acetate, succinate, d-tartrate, l-tartrate, citrate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.

Pharmaceutically acceptable cationic salts of the compounds used in this invention may be readily prepared, where appropriate, by reacting the free acid form of said compound with an appropriate base, usually one equivalent, in a co-solvent. Typical bases are sodium hydroxide, sodium methoxide, sodium ethoxide, sodium hydride, potassium methoxide, magnesium hydroxide, calcium hydroxide, benzathine, choline, diethanolamine, piperazine and tromethamine. The salt is isolated by concentration to dryness or by addition of a non-solvent. In many cases, salts are


preferably prepared by mixing a solution of the acid with a solution of a different salt of the cation (sodium or potassium ethylhexanoate, magnesium oleate), and employing a solvent (e.g., ethyl acetate) from which the desired cationic salt precipitates, or can be otherwise isolated by concentration and/or addition of a non-solvent.

The acid addition salts of the compounds used in this invention may be readily prepared by reacting the free base form of said compound with the appropriate acid. When the salt is of a monobasic acid (e.g., the hydrochloride, the hydrobromide, the p-toluenesulfonate, the acetate), the hydrogen form of a dibasic acid (e.g., the hydrogen sulfate, the succinate) or the dihydrogen form of a tribasic acid (e.g., the dihydrogen phosphate, the citrate), at least one molar equivalent and usually a molar excess of the acid is employed. However when such salts as the sulfate, the hemisuccinate, the hydrogen phosphate or the phosphate are desired, the appropriate and exact chemical equivalents of acid will generally be used. The free base and the acid are usually combined in a co-solvent from which the desired salt precipitates, or can be otherwise isolated by concentration and/or addition of a non-solvent.

In addition, the GHSs and other compounds which may be used in accordance with this invention, prodrugs thereof and pharmaceutically acceptable salts thereof or of said prodrugs, may occur as hydrates or solvates. Said hydrates and solvates are also within the scope of the invention.

The compounds used in the methods of the present invention may have at least one asymmetric center as noted, e.g., by the asterisk in the structural Formula I-A below. Additional asymmetric centers may be present in the compounds of Formula I depending upon the nature of the various substituents on the molecule. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as separated, pure or partially purified optical isomers, racemic mixtures or diastereomeric mixtures thereof, be included within the scope of the methods and combinations of the instant invention. In the case of the asymmetric center represented by the asterisk, it has been found that the absolute stereochemistry of the more active and thus more preferred isomer is shown in Formula I-A below:





I-A

With the  $R^4$  substituent as hydrogen, the spatial configuration of the asymmetric center corresponds to that in a D-amino acid. In most cases this is also designated an R-configuration although this will vary according to the values of  $R^3$  and  $R^4$  used in making R- or S-stereochemical assignments.

Certain compounds within the scope of the combinations, pharmaceutical compositions, kits and methods of this invention may have the potential to exist in tautomeric forms. All tautomers of a compound of the present invention are within the scope of this invention. Also, for example, all keto-enol or imine-enamine forms of the compounds are included in this invention.

Those skilled in the art will recognize that the compound names contained herein may be based on a particular tautomer of a compound. While the name for only a particular tautomer may be used, it is intended that all tautomers are encompassed by the name of the particular tautomer and all tautomers are considered part of the present invention.

A GHS is a compound that, when administered to a patient, increases the production and/or secretion of growth hormone when compared with baseline plasma concentrations of growth hormone. Thus, to identify a GHS, one need simply measure the baseline plasma concentrations of growth hormone over a time period, typically one day, and compare the plasma concentrations of growth hormone after administration of a GHS with the baseline concentration over the time period. Various examples of GHSs are disclosed herein. It is contemplated that any GHS can be used in the present administration methods.

The identification of a compound as a "growth hormone secretagogue" which is able to directly or indirectly stimulate or increase the endogenous release of growth hormone in an animal may be readily determined without undue experimentation by methodology well known in the art, such as the assay described by Smith et al., Science, **260**, 1640-1643 (1993) (see text of Figure 2 therein). In a typical

experiment, pituitary glands are aseptically removed from 150-200 g Wistar male rats and cultures of pituitary cells are prepared according to Cheng et al., *Endocrinol.*, **124**, 2791-2798 (1989). The cells are treated with the subject compound and assayed for growth hormone secreting activity, as described by Cheng et al. (*ibid.*).

- 5 In particular, the GHS activity of a compound which may be used in the present invention may be determined by this assay. Compounds which display GHS activity in this assay are useful in treating systemic lupus erythematosus and intestinal bowel disease as described herein.

- 10 This particular application of GHS provides unexpected benefits relative to the administration of exogenous growth hormone. In particular, the GHS enhances the normal pulsatile releases of endogenous growth hormone and thus is more likely to reproduce the natural pattern of endogenous growth hormone release (see *J. Clin. Endocrinol. Metab.* **81**: 4249-4257, 1996). GHSs which are orally active also have the benefit of being able to be administered orally, rather than just intravenously,  
15 intraperitoneally or subcutaneously.

- In view of their use according to the present invention, the GHSs used in the present invention may be formulated into various pharmaceutical forms for administration purposes. A GHS may be administered, alone or in combination, by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous  
20 injection, or implant), nasal, vaginal, rectal, sublingual, or topical routes of administration and can be formulated with pharmaceutically acceptable vehicles, diluents or carriers to provide dosage forms appropriate for each route of administration.

- Solid dosage forms for oral administration include capsules, tablets, pills,  
25 powders and granules and for companion animals the solid dosage forms include an admixture with food and chewable forms. In such solid dosage forms, the compounds and combinations of this invention can be admixed with at least one inert pharmaceutically acceptable carrier, vehicle or diluent such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional  
30 substances other than such inert carriers, vehicles or diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings. In the case of chewable forms, the dosage form may comprise flavoring agents and perfuming agents.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert vehicles, carriers or diluents commonly used in the art, such as water. Besides such inert vehicles, carriers or diluents, such compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.

Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.

Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, which may also be a prodrug or a pharmaceutically acceptable salt of a prodrug, excipients such as coca butter or a suppository wax. Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.

The dosage of active ingredients in the compositions, methods and combinations of the present invention may be varied; however, it is necessary that the amount of the active ingredients be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. Generally, dosage levels of between 0.001 to 10 mg/kg of body weight daily are administered to humans and other animals, e.g., mammals, to obtain effective release of growth hormone. A preferred dosage range in humans is 0.01 to 5.0 mg/kg of body weight daily which can be administered as a single dose or divided into multiple doses.

A preferred dosage range in animals other than humans is 0.01 to 10.0 mg/kg of body weight daily which can be administered as a single dose or divided into multiple doses. A more preferred dosage range in animals other than humans is 0.1

to 5 mg/kg of body weight daily which can be administered as a single dose or divided into multiple doses.

Where the tartrate salt or other pharmaceutically acceptable salt of the above compounds is used in the present invention, the skilled person will be able to  
5 calculate effective dosage amounts by calculating the molecular weight of the salt form and performing simple stoichiometric ratios.

Also, the present invention includes within its scope the use of a GHS according to the present invention, alone or in combination with another GHS, such as those referenced herein, including the growth hormone releasing peptides GHRP-  
10 6 and GHRP-1 (described in U.S. Patent No. 4,411,890 and International Patent Applications, Publication Nos. WO 89/07110, WO 89/07111) and GHRP-2 (described in WO 93/04081) and B-HT920, as well as hexarelin and growth hormone releasing hormone (GHRH, also designated GRF) and its analogs, and growth hormone and its  
15 analogs, or in combination with other therapeutic agents, such as  $\beta$ -adrenergic agonists such as clonidine or serotonin 5HTD agonists such as sumatriptan, or agents which inhibit somatostatin or its release such as physostigmine and pyridostigmine. Preferably, the GHS may be used in combination with growth hormone releasing factor or an analog of growth hormone releasing factor.

In addition, the present invention includes within its scope the use of a  
20 pharmaceutical composition according to the present invention comprising, as an active ingredient, at least one GHS in association with a pharmaceutical carrier, vehicle or diluent.

It will be known to those skilled in the art that other compounds may be used in an effort to treat systemic lupus erythematosus. Combinations of these therapeutic  
25 agents, some of which have been mentioned herein, with a GHS will bring additional complementary, and potentially synergistic properties to enhance the desirable properties of these various therapeutic agents. Systemic lupus erythematosus treating agents other than those described herein are also within the scope of the combinations of this invention. In these combinations, the GHS and the other  
30 therapeutic agent(s) may be independently present in the dose ranges from 0.01 to 1 times the dose levels which are effective when these compounds and secretagogues are used singly.

It will also be known to those skilled in the art that other compounds may be used in an effort to treat IBD such as Crohn's disease and ulcerative colitis.

Combinations of these therapeutic agents, some of which have been mentioned herein, with a GHS will bring additional complementary, and potentially synergistic properties to enhance the desirable properties of these various therapeutic agents. IBD treating agents other than those described herein are also within the scope of the combinations of this invention. In these combinations, the GHS and the other therapeutic agent(s) may be independently present in the dose ranges from 0.01 to 1 times the dose levels which are effective when these compounds and secretagogues are used singly.

Typically, the individual daily dosages for these combinations may range from about one-fifth of the minimally recommended clinical dosages to the maximum recommended levels for the entities when they are given singly. These dose ranges may be adjusted on a unit basis as necessary to permit divided daily dosage and, as noted above, the dose will vary depending on the nature and severity of the disease, weight of patient, special diets and other factors.

These combinations may be formulated into pharmaceutical compositions as known in the art and as discussed herein.

Since the present invention has an aspect that relates to treatment with a combination of active ingredients which may be administered separately, the invention also relates to combining separate pharmaceutical compositions in kit form.

The kit comprises two separate pharmaceutical compositions: a GHS, a prodrug thereof or a pharmaceutically acceptable salt of said GHS or said prodrug; and a second therapeutic agent as described herein. The kit comprises a container for containing the separate compositions such as a divided bottle or a divided foil packet, however, the separate compositions may also be contained within a single, undivided container. Typically, the kit comprises directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.

An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are

formed in the plastic foil. The recesses have the size and shape of the tablets or capsules to be packed. Next, the tablets or capsules are placed in the recesses and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are sealed in the recesses between the plastic foil and the sheet. Preferably, the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.

It may be desirable to provide a memory aid on the kit, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the dosage form so specified should be ingested. Another example of such a memory aid is a calendar printed on the card e.g., as follows "First Week, Monday, Tuesday, ...etc.... Second Week, Monday, Tuesday,..." etc. Other variations of memory aids will be readily apparent. A "daily dose" can be a single tablet or capsule or several tablets or capsules to be taken on a given day. Also, a daily dose of a second therapeutic agent as described herein can consist of one tablet or capsule while a daily dose of the GHS, prodrug thereof or pharmaceutically acceptable salt of said GHS or said prodrug can consist of several tablets or capsules and vice versa. The memory aid should reflect this.

In another specific embodiment of the invention, a dispenser designed to dispense the daily doses one at a time in the order of their intended use is provided. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter which indicates the number of daily doses that has been dispensed. Another example of such a memory-aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.

The utility of the compounds described herein in the methods of the present invention are demonstrated by their activity in one or more of the assays which are described in International Application Publication Number WO97/24369.

It will be understood that the practice of the present invention encompasses all of the usual variations, adaptations or modifications as come within the scope of the following claims and their equivalents.

0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220  
2221  
2222  
2223  
2224  
2225  
2226  
2227